MedTrace Logo

RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe

NCT00688623 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2019-01-25

Study results available
· View outcomes & findings →

Summary

To evaluate the preliminary efficacy and safety of RAD001 as monotherapy for first-line treatment of patients with metastatic papillary carcinoma of the kidney.

Conditions

  • Advanced and Metastatic Silent Neuro-Endocrine Tumors
  • Carcinoma
  • Neuroendocrine
  • Non Functioning Neuroendocrine Tumors (NETs)
  • Non Syndromic Neuroendocrine Tumors
  • Carcinoids
  • Non Functioning

Interventions

DRUG

Everolimus

Everolimus 5 mg tablets were supplied in blister packs

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-24
Primary Completion
2016-11-07
Completion
2016-11-07

Countries

  • France
  • Germany
  • Italy
  • Netherlands
  • Poland
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00688623 on ClinicalTrials.gov